Please login to the form below

Not currently logged in
Email:
Password:

J&J appoints quality-control chief

Johnson & Johnson has created a new position at the company to oversee all quality, manufacturing and compliance issues 

In the wake of a series of major recalls of its nonprescription medicines, Johnson & Johnson (J&J) has created a new position at the company to oversee all quality, manufacturing and compliance issues.

Ajit Shetty, who is chairman of the board and managing director of the J&J subsidiary Janssen Pharmaceutica, has been tapped to fill the new post. He will serve as a corporate vice president of J&J, reporting directly to company CEO William Weldon, and will oversee quality improvement efforts for J&J's pharmaceutical, consumer products, medical device and diagnostics groups.

Shetty has been with J&J since 1976. He was raised in India but holds an MBA from Carnegie Mellon University in the US, as well as a PhD from Trinity College/Cambridge University in the UK.

In addition, J&J said it has appointed chief quality officers for each of its three major business units. Those positions will report to Shetty.

The recalls, which caused a PR crisis for J&J, involved Children's Tylenol, Motrin and St Joseph aspirin, the allergy drug Benadryl, the antacid Rolaids and Simply Sleep pills.

The products were manufactured at a Pennsylvania factory that has been temporarily shuttered, as well as at another facility in Puerto Rico. Some products were contaminated with bacteria, while others were made with the wrong amount of active ingredient, and still others contained metal shavings.

19th August 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....